Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.26.4 (RNase H)
 2,751 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Antisense oligonucleotide (AS-ODN) inhibition of angiotensin receptors (AT1-R) offers a potentially novel therapeutic approach for hypertension, left ventricular hypertrophy and other aspects of cardiovascular disease. To clarify questions concerning cellular uptake and retention of these oligos, we quantified the trafficking and stability of phosphorothioated modified AS-ODN to AT1 receptor mRNA in adrenal cells, using visual and chromatographic analysis. The AS-ODN to AT1 receptor mRNA was effective in significantly inhibiting AT1 receptor binding in a dose dependent manner. FITC-labeled ODNs were used to determine the cellular uptake in bovine adrena cortex cells; using confocal microscopy, rapid cellular uptake of 15-mer ODNs was observed. Uptake is initially rapid (30 min to 4 h) followed by a slower uptake process 24 h and after. The cellular accumulation of ODN involves a dynamic balance between influx and efflux processes. Efflux of FITC-ODN had a f1/2 = 4.6 days. Uptake was time and dose dependent. No obvious degradation of intracellular ODNs occurred as shown by intact peaks for 15-mer ODN on thin layer chromatography. The results suggest that the AS-ODN to AT1 receptor mRNA was resistant to cellular nucleases. The FITC-ODN accumulated mainly in the nucleus and remained there intact for up to 3 days. No significant change in target mRNA was observed by quantitative RT-PCR. Therefore the antisense inhibition mechanism of this ODN does not appear to stimulate RNase H or block transcription. Since the ODN accesses the nucleus, the results imply that the ODN inhibits specific mRNA transport into the cytoplasm. The data show that AS-ODN, for inhibition of AT1 receptors, is rapidly taken up and stable in cells and produces specific inhibition of AT1 receptors.
 ...
PMID:Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. 924 81

Multiple, diverse sites in the coding region of the angiotensin type-1 receptor mRNA were targeted with 2'-deoxyribonucleotide antisense oligonucleotides (ONs). The uptake of 1 microM concentration of these ONs into Chinese hamster ovary cells was facilitated by the use of cationic liposomes. The antisense sequences reduced binding of 125I-angiotensin II by 57-73%, while mismatch ONs and reverse sequence ONs produced little reduction in receptor binding. These reductions in AT1 receptor binding were accompanied by comparable decreases in AT1 receptor mRNA levels. Furthermore, mRNA cleavage fragments corresponding in size to 3'-cleavage fragments were observed with two of the antisense ONs, consistent with the involvement of an RNase H-type enzyme. When 2'-methoxyribonucleotide analogs of these same sequences were tested, AT1 receptor mRNA levels were unchanged even though small reductions in AngII binding were observed. Antisense effects seen with these 2'-methoxyribonucleotide sequences may have arisen through a translational arrest mechanism. Direct comparisons between 2'-deoxyribonucleotide analogs and their 2'-methoxyribonucleotide counterparts show that antisense effects are significantly larger when they are mediated through an RNase H-type mechanism. 2'-methoxyribonucleotide sequences were most effective when they were directed against the translation initiation codon.
 ...
PMID:Regulation of the angiotensin type-1 receptor by antisense oligonucleotides occurs through an RNase H-type mechanism. 1003 4